Dielectrophoresis-based microfluidic platforms for cancer diagnostics.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Research

Background:

• Dielectrophoresis (DEP) offers unique advantages for microfluidic applications, including specificity, cost-effectiveness, and minimal sample volume requirements.
• These characteristics make DEP-based microfluidic platforms highly suitable for developing advanced cancer diagnostic tools.
• Recent technological progress has accelerated the development of these platforms for clinical use.

Purpose of the Study:

• To provide a comprehensive review of recent developments in DEP-enabled microfluidic platforms for cancer diagnostics.
• To critically analyze individual studies based on platform features, performance, and clinical applicability.
• To identify novel techniques, strategies, and design configurations that enhance existing DEP technologies.

Main Methods:

• Systematic review and critical analysis of recent literature on DEP-enabled microfluidic platforms for cancer diagnostics.
• Categorization of studies based on the target cancer cell type.
• Evaluation of platform features, performance metrics, clinical functionalities, and sample types used.

Main Results:

• Detailed analysis of various DEP microfluidic platforms tailored for specific cancer types.
• Discussion of performance benchmarks, including sensitivity and specificity.
• Highlighting innovative approaches in platform design and integration for improved clinical utility.

Conclusions:

• DEP-enabled microfluidics represent a significant advancement in cancer disease diagnostics.
• The reviewed platforms demonstrate potential for specific, cost-effective, and low-volume cancer cell detection.
• Future trends indicate continued innovation in design, functionality, and clinical translation of these technologies.